Skip to content
Medical Health Aged Care

Lighten the overload of Australia’s most common genetic disorder

Haemochromatosis Australia 2 mins read

MEDIA RELEASE 


The Bolte Bridge, AAMI Park, Federation Square are among 100 well-known buildings and landmarks around Australia turning red every evening from tonight until -7 June, shining a light on an extremely common genetic condition that most people have never heard of.

It is part of a worldwide initiative to raise awareness of haemochromatosis – also known as iron overload – and to prompt people to get tested. Most people know that having too little iron in your body can cause anaemia, which is characterised by tiredness and lethargy, but few people know that the same symptoms can also be caused by having too much iron.

The hereditary condition, which is passed on from both biological parents, is simple to detect and treat but if undiagnosed or ignored can lead to serious and life-threatening illness, including liver disease and diabetes. One in seven Australians carry one copy of the defective gene, while and one in 200 Australians have two copies, which puts them at high risk of developing the condition.

Dr Dan Johnstone, an iron researcher who also has the condition, says early detection is key to minimising or preventing permanent damage. “Awareness of haemochromatosis is more important now than ever as early diagnosis will help save lives, cut health costs and reduce unnecessary suffering for so many individuals and families. Everybody is different; some people will have early symptoms of fatigue or joint aches while others won’t know they have the condition until the damage is already done. Anyone who suspects they may have this condition should ask their GP for a blood test. Haemochromatosis is not a burden in your life if you get on to it early. Early diagnosis is key to managing and reducing complications. It is usually managed by a regime of therapeutic blood donations, at an Australian Red Cross Lifeblood donor centre. This is a classic win-win situation, benefiting both the individual and the community,” said Dr Johnstone.

Haemochromatosis Australia spokesperson, Tony Moorhead, said, “Despite being the most common genetic disorder in Australia, haemochromatosis is often underdiagnosed because people don’t know about it and symptoms are non-specific. Unfortunately, most of those affected aren’t diagnosed until aged in their mid-forties and already suffering ill health. “There are people with the condition who should have been diagnosed decades earlier. This would have reduced the suffering, medical cost and even loss of life that results from iron overload. If haemochromatosis is detected early enough it is completely preventable – those affected need never get sick, they simply need to donate blood to maintain normal iron levels and their health.” Mr Moorhead says. “Hereditary haemochromatosis is estimated to cost Australia’s health system about $280 million annually and to add further cost burdens by compounding other chronic conditions.” Haemochromatosis is easy to test, simple to treat but tragic to ignore. -

 

ENDS Landmarks lighting up can be found here: www.ha.org.au/whats-on/world-haemochromatosis-week/lighten-the-overload/ 


Key Facts:

* Australia's most common genetic disorder, that most have never heard of

* World Haemochromatosis Awareness Week June 1 - 7 

* Landmarks lighting up red can be found here: www.ha.org.au/whats-on/world-haemochromatosis-week/lighten-the-overload/ 

*Interviews available


About us:

To find out more visit www.ha.org.au/haemochromatosis


Contact details:

Kellie Curtain M: 0412339690 [email protected] 

Media

More from this category

  • Medical Health Aged Care
  • 04/03/2026
  • 10:56
Roots

Roots Corporation Announces Strategic Review

TORONTO–BUSINESS WIRE– Roots Corporation (“Roots,” or the “Company”) (TSX: ROOT) announced that its Board of Directors (the “Board”) has initiated a review of strategic…

  • Contains:
  • Medical Health Aged Care
  • 04/03/2026
  • 08:56
Monash University

Monash University and Seaport Therapeutics Awarded up to $21 Million AUD from ARPA-H to Advance GlyphCeleTM, the First Oral Therapeutic Designed to Restore Gut Lymphatic Function

ARPA-H award supports the development of an oral prodrug, based on the Glyph™ platform initially developed at the Monash Institute of Pharmaceutical Sciences (MIPS), to address dysfunctional gut lymphatics linked to metabolic disease and pancreatic cancer. Monash University has announced the award of support from the Advanced Research Projects Agency for Health (ARPA-H) to advance an oral prodrug of celecoxib – using the GlyphTM platform and designed to deliver therapy directly to the gut lymphatics – aiming to improve lymphatic function and advance the treatment of metabolic disease and pancreatic cancer by directly addressing local inflammation and lymphatic dysfunction. The…

  • Medical Health Aged Care, Women
  • 04/03/2026
  • 06:00
Australia New Zealand Gynaecological Oncology Group (ANZGOG)

STRIVE clinical trial now available in Aotearoa New Zealand to improve outcomes in vulvar cancer

MEDIA RELEASE: Wednesday,4March2025 The Australian New Zealand Gynaecological Oncology Group (ANZGOG) in partnership with the Canadian Cancer Trials Group (CCTG) announces the local opening of theSTRIVEclinical trial– Stratification of Vulvar Squamous Cell Carcinoma by HPV and p53 status to Guide Excisionclinical trial (CCTG Protocol VU.2; ANZGOG Protocol ANZGOG2109/2021). STRIVErepresentsan important stepforward in advancing evidence-based surgical management for women diagnosed with vulvar squamous cell carcinoma (VSCC). About the STRIVE Trial STRIVE is an international, prospective, stratification study designed to refine surgical decision-making for patients withprimary vulvar squamous cell carcinoma(VSCC) based ontumourbiology. The study is led globally by the CCTG and led…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.